|
Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line Helicobacter pylori eradication
|
Arash Kazemi    , Ali Rahimi Petrudi , Iradj Maleki , Hafez Fakheri , Tarang Taghvaei , Vahid Hosseini , Mohammad Valizadeh Toosi , Danial Masoumi , Zohreh Bari |
| Gut and Liver Research Center, Non-communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran , zohreb252@yahoo.com |
|
|
Abstract: (892 Views) |
Background: Helicobacter pylori (H. pylori) has infected about 50% of the world’s population and it is the main cause for peptic ulcer, gastric adenocarcinoma and even a major cause for gastric MALT lymphoma.
Methods: This study was performed in Mazandaran, Sari, situated in North of Iran. Three-hundred and twenty-eight adult patients with endoscopically approved gastric or duodenal ulcers or erosions and H. pylori infection were randomly divided into 2 groups to receive either 14 days PABT (Pantoprazole 40 mg, Amoxicillin 1 g, Bismuth 425 mg (all twice daily) and Tetracycline 500 mg four times a day) and PACM (Pantoprazole 40 mg, Amoxicillin 1g, Clarithromycin 500 mg, and Metronidazole 500 mg, all twice daily). To evaluate H. pylori eradication, fecal H. pylori antigen test was performed 8 weeks after treatment.
Results: The eradication rates were 94.51% in the PATB and 91.46% in PACM group based on the intention to treat analysis. Moreover, the eradication rates were 95.58% and 92.72% according to per-protocol analysis, respectively. Also, both groups had very low rates of severe side effects.
Conclusion: Regarding the ideal eradication rates achieved by both treatment groups and the low rates of severe side effects, both treatment protocols can be prescribed for H. pylori eradication in North of Iran. |
|
| Keywords: Helicobacter pylori, Bismuth, tetracycline, concomitant, eradication |
|
|
Full-Text [PDF 678 kb]
(364 Downloads)
|
Type of Study: Original Article |
Subject:
Gastroentrology
Received: 2021/12/25 | Accepted: 2022/05/11 | Published: 2023/09/28
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
